Last updated: September 21, 2026
Istradefylline is a selective adenosine A2A receptor antagonist marketed as Nouriast in Japan and Nourianz in the United States. Kyowa Kirin owns the product globally and commercializes it directly in Japan and the United States. The drug is approved as an adjunct to levodopa and carbidopa for “off” episodes in adults with Parkinson’s disease.
The commercial opportunity is durable but specialized. Istradefylline addresses motor fluctuations in an established Parkinson’s market, yet it competes with inexpensive generic adjunctive therapies and has limited use outside the “off” episode population. Kyowa Kirin does not publicly report Nourianz or Nouriast revenue as a separate product line, so product-level revenue, margin and return-on-investment calculations are not available from company disclosures.
What is istradefylline and how is it used?
Istradefylline blocks adenosine A2A receptors in the indirect pathway of the basal ganglia. It does not replace dopamine and is used with levodopa-based therapy.
| Attribute |
Details |
| Active ingredient |
Istradefylline |
| U.S. brand |
Nourianz |
| Japanese brand |
Nouriast |
| Developer and originator |
Kyowa Kirin Co., Ltd. |
| U.S. approval |
August 27, 2019 |
| U.S. indication |
Adjunctive treatment to levodopa/carbidopa for “off” episodes in adults with Parkinson’s disease |
| Dosage forms |
20 mg and 40 mg tablets |
| Standard U.S. dose |
20 mg once daily; may increase to 40 mg once daily |
| Pharmacologic class |
Adenosine A2A receptor antagonist |
| U.S. regulatory pathway |
NDA 211150 |
| Biosimilar relevance |
None; this is a small-molecule drug |
The FDA label identifies dyskinesia, particularly at the 40 mg dose, as an important adverse event. Strong CYP3A4 inhibitors and inducers affect exposure, creating prescribing and market-access constraints for some patients. [1]
When did istradefylline enter the market?
Japan was the first major commercial market. Kyowa Kirin received Japanese approval for Nouriast in 2013. The U.S. approval followed in 2019 after earlier clinical and regulatory setbacks involving efficacy, study design and the interpretation of “off” time.
The U.S. approval expanded the addressable market but did not create a broad Parkinson’s disease therapy. Nourianz is used for a defined symptom-management segment: patients receiving levodopa/carbidopa who experience “off” episodes.
Istradefylline regulatory timeline
| Date |
Event |
| 2013 |
Nouriast approved in Japan for Parkinson’s disease |
| 2013 onward |
Japanese commercial launch and expansion through Kyowa Kirin’s domestic specialty portfolio |
| 2019 |
FDA approves Nourianz in the United States |
| 2019 onward |
U.S. launch through Kyowa Kirin’s commercial organization and specialty pharmacy channels |
| 2024 |
Five-year U.S. new chemical entity exclusivity period would ordinarily expire, subject to the applicable FDA exclusivity designation and any pediatric extension |
| Current commercial phase |
Mature Japan business with a later-stage U.S. growth and retention opportunity |
How large is the istradefylline market?
The relevant market is the global treatment market for Parkinson’s disease with motor fluctuations, not the entire Parkinson’s disease drug market.
Demand is supported by several factors:
- Parkinson’s disease prevalence rises with aging populations.
- Long-term levodopa treatment commonly produces wearing-off and “off” episodes.
- Istradefylline offers an oral, non-dopaminergic adjunct.
- The drug avoids some of the administration burdens associated with infusion and device-based therapies.
- Japanese physician familiarity with Nouriast supports retention in its home market.
Market constraints are equally important:
- The indication is limited to patients receiving levodopa/carbidopa with “off” episodes.
- Generic entacapone, dopamine agonists and monoamine oxidase-B inhibitors compete for adjunctive use.
- Advanced therapies, including deep-brain stimulation, intestinal levodopa infusion and subcutaneous delivery systems, target more severe disease.
- U.S. payer coverage can require prior authorization or step therapy.
- A portion of the addressable population may be managed by dose adjustment or other generic adjuncts.
Istradefylline therefore occupies a specialty position rather than a mass-market neurological position.
What are the main competitors to istradefylline?
Istradefylline competes against both branded advanced therapies and low-cost generic adjuncts.
| Therapy |
Mechanism or approach |
Competitive relationship |
| Entacapone and generic combination products |
Catechol-O-methyltransferase inhibition |
Direct oral adjunct competition |
| Opicapone |
Long-acting COMT inhibition |
Direct oral adjunct competition, particularly for wearing-off |
| Rasagiline and selegiline |
MAO-B inhibition |
Alternative oral adjuncts |
| Pramipexole, ropinirole and rotigotine |
Dopamine agonism |
Alternative adjunctive therapy, with different tolerability risks |
| Amantadine products |
Primarily dyskinesia management |
Overlapping motor-complication treatment |
| Apomorphine products |
Rescue or continuous dopaminergic therapy |
Used in more advanced or acute “off” management |
| Levodopa inhalation products |
Rescue treatment for “off” episodes |
Different delivery and use pattern |
| Deep-brain stimulation |
Surgical neuromodulation |
Advanced-therapy alternative |
| Levodopa infusion systems |
Continuous drug delivery |
More invasive option for advanced disease |
Istradefylline’s differentiation is its non-dopaminergic mechanism and oral once-daily dosing. Its principal weakness is the absence of a major administration or efficacy advantage over established generic adjuncts in every patient segment.
What is the financial trajectory of istradefylline?
Kyowa Kirin does not disclose product-level net sales for Nouriast or Nourianz in its standard annual reports. The company reports consolidated results and business-segment performance, generally grouping products within the Pharmaceuticals segment. As a result, the product’s exact revenue trajectory cannot be independently calculated from public filings.
The commercial trajectory can be divided into three phases.
Japan: mature and defensive revenue
Nouriast has had a long Japanese market life since 2013. Revenue in Japan is likely shaped by:
- Repeated prescription use in chronic Parkinson’s disease.
- Generic competition in the wider adjunct market.
- National drug-price revisions.
- Reimbursement controls under Japan’s pricing system.
- Kyowa Kirin’s established neurologic and specialty commercial infrastructure.
Japan provides recurring revenue but has a lower probability of rapid expansion than a newly launched therapy.
United States: launch, access expansion and maturity
Nourianz entered the United States in 2019. The U.S. market offered higher price potential than Japan but required investment in:
- Neurologist education.
- Diagnosis and documentation of “off” episodes.
- Payer access and prior-authorization support.
- Specialty pharmacy distribution.
- Patient adherence and copayment programs.
U.S. revenue growth would depend on increased diagnosis, broader formulary access and sustained prescribing against generic alternatives. The product’s commercial ceiling is limited by its narrow label and the number of patients considered suitable for oral adjunctive treatment.
Post-exclusivity phase: price and volume pressure
The end of regulatory exclusivity increases the probability of generic development, although it does not guarantee an immediate generic launch. Generic entry would likely pressure:
- Net price.
- Payer coverage.
- Patient copayment economics.
- Physician willingness to initiate treatment.
- Kyowa Kirin’s return on U.S. commercial spending.
A product with an established prescriber base can retain branded volume after generic entry, but that retention usually requires meaningful differentiation, payer contracting or patient-support investment.
What is the Orange Book status of Nourianz?
Nourianz is listed in the FDA’s Drugs@FDA and Orange Book systems under NDA 211150. The Orange Book is the authoritative source for FDA-listed patents and applicable market-exclusivity information. Patent listings and expiration dates can change through corrections, patent-term adjustments, pediatric extensions and regulatory updates. [2]
The key legal distinction is between:
- FDA regulatory exclusivity, which restricts certain abbreviated applications for a defined period; and
- Patent protection, which can support litigation or delay approval if a generic applicant files a Paragraph IV certification.
The U.S. approval date was August 27, 2019. If FDA granted five-year new chemical entity exclusivity, the ordinary regulatory exclusivity period would run to August 27, 2024, before any pediatric extension. A generic applicant could still prepare and file an ANDA during the exclusivity period, but FDA approval would be delayed until the exclusivity expires.
What patents protect istradefylline and its formulations?
Istradefylline’s earliest protection originated in compound and use patents covering adenosine A2A receptor antagonists. Those foundational rights were filed well before the U.S. launch and are unlikely to provide a long remaining exclusionary period in the United States.
The commercially relevant patent questions are narrower:
- Whether any U.S. patent covering the active ingredient remained unexpired after the 2019 launch.
- Whether Orange Book-listed patents cover the tablet formulation, dosage regimen or method of use.
- Whether later patents cover specific patient populations, combination treatment or manufacturing processes.
- Whether unlisted process patents could create practical supply barriers without blocking an ANDA.
No public evidence establishes a broad, late-expiring U.S. formulation estate comparable to the patent positions supporting some high-value specialty drugs. The likely protection profile is therefore more dependent on the original regulatory exclusivity period, brand recognition, manufacturing know-how and commercial execution than on a large portfolio of late-life formulation patents.
Manufacturing and intellectual-property barriers
Manufacturing risk is moderate rather than extreme. Istradefylline is a small molecule in an oral tablet, so it does not face the cell-line, comparability and cold-chain barriers associated with biologics. A generic manufacturer would still need to establish:
- Active pharmaceutical ingredient supply.
- Bioequivalence.
- Impurity controls.
- Stable tablet manufacturing.
- Regulatory documentation.
- Reliable commercial-scale production.
These requirements create execution risk but are unlikely to block a capable generic manufacturer indefinitely.
Which companies are challenging istradefylline exclusivity?
No major, publicly established Paragraph IV litigation campaign against Nourianz is identified in the core public regulatory record through the latest generally available information. The absence of reported litigation does not establish that no ANDA has been filed. ANDA filings and Paragraph IV notices are often disclosed through litigation records, FDA correspondence or company announcements rather than through a complete public list.
The most probable generic challengers would be U.S. generic manufacturers with experience in CNS tablets and specialty pharmacy products. Competitive entry could also come from authorized or semi-branded generic strategies if Kyowa Kirin or a partner elects to defend volume through pricing.
What generic launch scenarios exist for istradefylline?
| Scenario |
Timing |
Commercial effect |
| No immediate generic filing |
After regulatory exclusivity |
Continued branded sales, with patent and market-access monitoring |
| First filer with Paragraph IV certification |
Potential 30-month litigation stay if suit is timely filed |
Delayed approval while litigation proceeds |
| Early settlement |
Before trial or judgment |
Entry date depends on settlement terms |
| Single generic launch |
After approval or settlement |
Initial price erosion and gradual volume migration |
| Multiple generic launch |
Several manufacturers enter |
More rapid net-price compression |
| Authorized generic strategy |
Brand-linked generic supply |
May protect total franchise volume but reduce branded price |
The most material risk is not only patent expiry. It is a coordinated payer shift from Nourianz to generic istradefylline after the first approved ANDA.
How strong is the istradefylline patent estate?
The patent estate appears moderate to weak as a long-term U.S. exclusion strategy unless later Orange Book-listed patents extend beyond the core compound protection.
Strengths include:
- An established FDA-approved product.
- Defined use in a clinically recognized Parkinson’s disease segment.
- Proprietary manufacturing and regulatory knowledge.
- Kyowa Kirin’s ability to manage Japanese and U.S. commercialization.
Weaknesses include:
- Small-molecule chemistry with an older discovery and development history.
- A narrow indication that limits market expansion.
- Generic alternatives in the same treatment pathway.
- No biologic manufacturing barrier.
- Limited publicly disclosed product-level revenue to support aggressive life-cycle investment.
- Likely reliance on regulatory exclusivity and commercial execution rather than a dense late-expiring patent thicket.
The estate is stronger as a near- to medium-term commercial franchise than as a long-duration patent monopoly.
What licensing deals affect istradefylline?
Kyowa Kirin is the originator and global rights holder. Public commercial disclosures identify Kyowa Kirin as responsible for Nouriast in Japan and Nourianz in the United States. No major independent global licensing transaction is central to the current commercial structure.
The absence of a major license means Kyowa Kirin retains more economics but also bears U.S. launch, market-access and post-exclusivity risk. It also limits the opportunity to offset development and commercialization costs through large upfront or milestone payments from a partner.
What is the FDA regulatory status of Nourianz?
Nourianz remains FDA approved for adults with Parkinson’s disease experiencing “off” episodes while taking levodopa/carbidopa. It is not a biologic and is not exposed to biosimilar substitution. Any competitive approval would proceed through the ANDA pathway for a small-molecule generic, assuming the applicant can demonstrate pharmaceutical equivalence and bioequivalence.
FDA safety labeling identifies dyskinesia, hallucinations, insomnia, nausea and other adverse reactions among the clinically relevant risks. Drug interactions involving CYP3A4 are important to prescribing and may influence use in patients receiving interacting medicines. [1]
What revenue exposure does Kyowa Kirin have?
Kyowa Kirin’s financial exposure to istradefylline is meaningful at the product level but not separately quantifiable from public consolidated reporting. The company’s revenue base includes multiple specialty and rare-disease products, so istradefylline is not equivalent to the company’s overall financial performance.
The principal exposure variables are:
- Japan prescription volume.
- U.S. patient adoption.
- Net price after rebates and discounts.
- Payer restrictions.
- Generic entry date.
- Physician retention after substitution.
- Cost of sales and commercial support.
- Kyowa Kirin’s ability to extend use through evidence generation without creating new approved indications.
Investors should treat istradefylline as a recurring specialty-product contributor, not as a standalone valuation driver unless Kyowa Kirin begins reporting product-level sales.
How does istradefylline compare with opicapone and entacapone?
Istradefylline has a differentiated mechanism and once-daily administration. Opicapone also offers once-daily dosing but works through COMT inhibition and is positioned more directly against wearing-off. Entacapone is older, widely available in generic form and generally has the strongest price advantage.
| Factor |
Istradefylline |
Opicapone |
Entacapone |
| Mechanism |
A2A antagonism |
COMT inhibition |
COMT inhibition |
| Generic pressure |
Emerging risk |
Brand and generic risk depending on market |
Established generic pressure |
| Dosing |
Once daily |
Once daily |
Often with each levodopa dose |
| Differentiation |
Non-dopaminergic adjunct |
Long-acting COMT inhibition |
Low-cost established adjunct |
| Commercial position |
Specialty branded adjunct |
Specialty branded or hybrid market |
Price-led adjunct |
| Main weakness |
Narrow segment and payer sensitivity |
Competing efficacy and access considerations |
Dosing burden and established low price |
Istradefylline can maintain a niche where physicians value its non-dopaminergic mechanism or where other adjuncts are poorly tolerated. It is less defensible when payers prioritize generic cost.
Key Takeaways
- Istradefylline is a mature Japanese product and a later-launched U.S. specialty drug.
- Kyowa Kirin markets Nouriast in Japan and Nourianz in the United States.
- The commercial indication is narrow: “off” episodes in levodopa/carbidopa-treated adults with Parkinson’s disease.
- Product-level revenue is not separately disclosed, preventing precise financial modeling.
- The U.S. market offers higher price potential but has greater payer, generic and commercial execution risk.
- The core patent position is unlikely to provide a long-duration U.S. barrier without meaningful later formulation or method-of-use patents.
- Biosimilar risk does not apply. The relevant threat is small-molecule generic substitution.
- The principal valuation variables are U.S. adoption, payer access, generic-entry timing and post-entry brand retention.
FAQs
Is istradefylline a generic drug?
Istradefylline is the active ingredient in the branded products Nouriast and Nourianz. Generic istradefylline may be developed through the ANDA pathway after applicable FDA exclusivity and patent barriers are resolved.
Does istradefylline treat Parkinson’s disease itself?
It treats motor “off” episodes associated with Parkinson’s disease. It is used as an adjunct to levodopa/carbidopa and is not a disease-modifying therapy.
Is Nourianz a biologic or biosimilar product?
No. Nourianz is an oral small-molecule tablet. Its competitive pathway is generic-drug approval, not biosimilar approval.
What is the biggest commercial risk for Nourianz?
The largest commercial risk is loss of branded volume and price after generic istradefylline becomes available. Payer substitution could accelerate the decline even if some physicians continue prescribing Nourianz.
Can Kyowa Kirin extend istradefylline exclusivity?
Potential mechanisms include valid later patents, pediatric exclusivity, approved new indications and commercial agreements. The value of any extension depends on whether it creates enforceable market protection and supports a meaningful patient population.
References
-
U.S. Food and Drug Administration. (2019). Nourianz (istradefylline) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2019). FDA approves new treatment for off episodes in adults with Parkinson’s disease. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-parkinsons-disease
-
Kyowa Kirin Co., Ltd. (2024). Integrated report and financial results materials. https://ir.kyowakirin.com/en/ir/library/annual.html
-
Pharmaceuticals and Medical Devices Agency. (2013). Nouriast tablets: Japanese regulatory information. https://www.pmda.go.jp/english/ 天天中彩票开奖
